Aequus Pharmaceuticals(DE:AEQ)
€0.01+0.00 (+20.00%)
DE:AEQ
Aequus Pharmaceuticals financials statements
€0.01
At close:+0.00 (+20.00%)
Aequus Pharmaceuticals (AEQ) Ratios
0 Followers
Aequus Pharmaceuticals Ratios
DE:AEQ's free cash flow for Q2 2025 was C$-46.87K. For the 2025 fiscal year, DE:AEQ's free cash flow was increased by C$0.00 and operating cash flow was C$-46.87K. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 24 | Mar 23 | Dec 21 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.09 | 0.38 | 1.46 | 7.20 |
| Quick Ratio | 0.04 | 0.07 | 0.34 | 1.41 | 6.88 |
| Cash Ratio | 0.01 | 0.04 | 0.11 | 0.97 | 4.47 |
| Solvency Ratio | -0.28 | -0.53 | -1.00 | -0.66 | -0.33 |
| Operating Cash Flow Ratio | -0.24 | -0.48 | -0.82 | -0.48 | -2.09 |
| Short-Term Operating Cash Flow Coverage | -0.27 | -0.52 | -21.90 | -0.61 | 0.00 |
| Net Current Asset Value | C$ -6.97M | C$ -4.94M | C$ -2.17M | C$ 1.03M | C$ 207.67K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 8.26 | 4.66 | 0.46 | 0.50 | 0.74 |
| Debt-to-Equity Ratio | -1.02 | -1.18 | -0.57 | 1.22 | 4.05 |
| Debt-to-Capital Ratio | 41.99 | 6.58 | -1.31 | 0.55 | 0.80 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.78 |
| Financial Leverage Ratio | -0.12 | -0.25 | -1.23 | 2.43 | 5.46 |
| Debt Service Coverage Ratio | -0.28 | -0.59 | -9.45 | -0.51 | -0.61 |
| Interest Coverage Ratio | -8.40 | -19.43 | -11.67 | -2.98 | -1.00 |
| Debt to Market Cap | 4.64 | 1.32 | 0.02 | 0.13 | 0.18 |
| Interest Debt Per Share | 0.05 | 0.04 | 0.01 | 0.02 | 0.03 |
| Net Debt to EBITDA | -3.66 | -1.83 | -0.19 | 0.17 | -1.92 |
| Profitability Margins | |||||
| Gross Profit Margin | 34.23% | 56.36% | 83.08% | 99.05% | 100.00% |
| EBIT Margin | -329.37% | -1106.15% | -217.14% | -49.90% | -20.28% |
| EBITDA Margin | -306.72% | -1051.95% | -207.73% | -45.19% | -12.14% |
| Operating Profit Margin | -364.10% | -1106.45% | -181.05% | -49.89% | -20.12% |
| Pretax Profit Margin | -372.74% | -1163.11% | -232.65% | -66.66% | -40.32% |
| Net Profit Margin | -372.74% | -1163.11% | -232.65% | -66.66% | -40.32% |
| Continuous Operations Profit Margin | -372.74% | -1163.11% | -232.65% | -66.66% | -40.32% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 102.37% | 105.12% | 128.50% | 133.62% | 200.43% |
| Return on Assets (ROA) | -272.11% | -272.94% | -189.78% | -41.62% | -33.35% |
| Return on Equity (ROE) | 33.74% | 69.05% | 232.61% | -101.15% | -182.13% |
| Return on Capital Employed (ROCE) | 35.48% | 76.01% | 364.01% | -71.61% | -18.96% |
| Return on Invested Capital (ROIC) | -753.79% | -366.30% | 491.76% | -34.12% | -18.00% |
| Return on Tangible Assets | -272.11% | -272.94% | -189.78% | -41.62% | -33.35% |
| Earnings Yield | -164.19% | -89.41% | -69.15% | -12.21% | -9.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.02 | 8.04 | 4.45 | 2.88 | 3.33 |
| Payables Turnover | 0.46 | 0.41 | 2.64 | 0.16 | 0.00 |
| Inventory Turnover | 6.66 | 0.90 | 2.49 | 0.18 | 0.00 |
| Fixed Asset Turnover | 1.13 | 0.39 | 1.75 | 11.20 | 7.08 |
| Asset Turnover | 0.73 | 0.23 | 0.82 | 0.62 | 0.83 |
| Working Capital Turnover Ratio | -0.11 | -0.09 | -8.14 | 1.54 | 1.72 |
| Cash Conversion Cycle | -695.87 | -448.41 | 90.40 | -118.18 | 109.74 |
| Days of Sales Outstanding | 36.44 | 45.37 | 82.03 | 126.53 | 109.74 |
| Days of Inventory Outstanding | 54.77 | 406.06 | 146.73 | 1979.77 | 0.00 |
| Days of Payables Outstanding | 787.08 | 899.84 | 138.37 | 2224.48 | 0.00 |
| Operating Cycle | 91.21 | 451.43 | 228.76 | 2106.30 | 109.74 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -458797.00 | 0.00 | -284.45 | -65.35 |
| Capital Expenditure Coverage Ratio | 0.00 | -458797.00 | 0.00 | -284.45 | -65.35 |
| Operating Cash Flow Coverage Ratio | -0.25 | -0.45 | -2.49 | -0.54 | -0.35 |
| Operating Cash Flow to Sales Ratio | -2.83 | -9.00 | -1.42 | -0.43 | -0.31 |
| Free Cash Flow Yield | -124.85% | -69.18% | -42.06% | -7.94% | -7.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.61 | -1.12 | -1.45 | -8.19 | -10.70 |
| Price-to-Sales (P/S) Ratio | 2.27 | 13.01 | 3.36 | 5.46 | 4.31 |
| Price-to-Book (P/B) Ratio | -0.21 | -0.77 | -3.36 | 8.28 | 19.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.80 | -1.45 | -2.38 | -12.60 | -13.68 |
| Price-to-Operating Cash Flow Ratio | -0.80 | -1.45 | -2.38 | -12.64 | -13.89 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.15 | -0.02 | -0.33 | 0.15 |
| Enterprise Value Multiple | -4.40 | -3.06 | -1.81 | -11.91 | -37.44 |
| Enterprise Value | 7.89M | 8.21M | 5.18M | 14.61M | 11.79M |
| EV to EBITDA | -4.40 | -3.06 | -1.81 | -11.91 | -37.44 |
| EV to Sales | 13.50 | 32.21 | 3.75 | 5.38 | 4.55 |
| EV to Free Cash Flow | -4.76 | -3.58 | -2.65 | -12.42 | -14.42 |
| EV to Operating Cash Flow | -4.76 | -3.58 | -2.65 | -12.46 | -14.64 |
| Tangible Book Value Per Share | -0.05 | -0.03 | -0.01 | 0.01 | 0.01 |
| Shareholders’ Equity Per Share | -0.05 | -0.03 | -0.01 | 0.01 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.02 | 0.03 |
| Net Income Per Share | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.13 | 1.05 | 1.07 | 1.34 | 1.99 |
| Research & Development to Revenue | 0.00 | 1.18 | 0.12 | 0.11 | 0.02 |
| SG&A to Revenue | 3.98 | 8.39 | 2.16 | 0.63 | 0.55 |
| Stock-Based Compensation to Revenue | 0.03 | 0.20 | 0.03 | 0.08 | 0.11 |
| Income Quality | 0.76 | 0.77 | 0.61 | 0.65 | 0.77 |
Currency in CAD
